Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

Dyne Therapeutics, Inc.: WELLINGTON MANAGEMENT GROUP LLP discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Wellington Management Group LLP disclosed a stake exceeding 5% in Dyne Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000902219-26-000331). The passive-investment disclosure signals that Wellington has built a meaningful position in the clinical-stage biotech, which develops targeted therapies for genetically driven muscle diseases. Crossing the 5% threshold makes Wellington a beneficial owner subject to Section 13 reporting obligations, and the filing's passive designation suggests the stake is held for investment rather than control. Investors will watch for any subsequent 13G amendments that reveal the precise size of the position or shifts in Wellington's holdings.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Dyne Therapeutics, Inc., Wellington Management Group LLP